Him’s & Hers Health Financial Update
Him’s & Hers Health (HIMS), a telemedicine platform, is set to release its third quarter financial results on Monday, November 3rd, after the market closes. Recently, the stock has dipped by 22% over the last month, mainly due to insider selling, but it’s still holding on with a year-to-date rise of about 83.4%. The company has expanded into international markets and areas like testosterone and menopause treatments. However, Wall Street seems cautious now, worried about the competitive landscape and ongoing legal and regulatory challenges.
In the lead-up to the financial report, HIMS also announced plans for a new GLP-1 “microdosing treatment,” which could be interesting to see how it plays out.
Analysts on Wall Street anticipate that HIMS will post earnings per share (EPS) of $0.09 for the third quarter, a drop from $0.32 in the same quarter last year. On the brighter side, revenues are expected to climb by 44.5% year-over-year, reaching approximately $580.24 million.
According to TipRanks, public and private investors currently hold the largest portion of HIMS shares at 56.57%. This is followed by ETFs at 22.2%, mutual funds at 19.96%, insiders possessing 0.98%, and other institutional investors holding 0.28%.
Ownership Breakdown
Looking closer at shareholders, Vanguard is the most significant stakeholder in Him’s & Hers Health, owning 7.52% of the company. iShares follows with a 7% stake.
In terms of ETFs, the iShares Core S&P Midcap ETF (IJH) holds 3.03% of HIMS stock, while the Vanguard Total Stock Market ETF (VTI) has a 2.49% share. For mutual funds, the Vanguard Index Fund owns roughly 6.97% of the company, with the Growth Fund of America holding about 4.7%.
Is HIMS Worth Buying?
As the third quarter results approach, Wall Street has reached a consensus rating of Hold for Him’s & Hers Health stock. This is based on 8 Hold ratings, 2 Buy ratings, and 2 Sell ratings. The average target price is $49.75, suggesting that there could be about a 13% upside potential.
